3 results
Approved WMORecruiting
The main objectives Investigate a first signal of efficacy, safety and tolerability of BI 706321 in combination with ustekinumab treatment compared to placebo with ustekinumab treatment in patients with moderately to severely active CD at 12 weeks.…
Approved WMOPending
To determine the safety and tolerability and to establish a preliminary RP2D and/or an MTD or an MAD of MK-4464 administered via IV infusion as monotherapy and in combination with pembrolizumab IV infusion
Approved WMOCompleted
The study aims to limit the use of anthracyclines and to reduce the dose of ATRA. Another aim is to stratify treatment by risk group: standard risk - WBC <10 x 109/l : high risk - WBC >=10 x 109/l. Furthermore this study aims to…